For the third quarter of the fiscal year ending October 2026, net sales were 2,567,467 thousand yen, operating income was 179,232 thousand yen, and quarterly net income was 174,484 thousand yen. Following the absorption of Hybrid Medical Co., Ltd., disclosures are now on a standalone basis. Full-year guidance has been revised: net sales of 3,367 million yen, operating income of 82 million yen, ordinary income of 76 million yen, and net income attributable to owners of the parent of negative 124 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4880","jir_company_name":"Cellsource Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4880-20260908-05.pdf","jir_short_summary":"For the third quarter of the fiscal year ending October 2026, net sales were 2,567,467 thousand yen, operating income was 179,232 thousand yen, and quarterly net income was 174,484 thousand yen. Following the absorption of Hybrid Medical Co., Ltd., disclosures are now on a standalone basis. Full-year guidance has been revised: net sales of 3,367 million yen, operating income of 82 million yen, ordinary income of 76 million yen, and net income attributable to owners of the parent of negative 124 million yen.","jir_summary":"### Overview of performance\nIn the third quarter financial results for the fiscal year ending October 2026, following the absorption of Hybrid Medical Co., Ltd., disclosures will be on a standalone basis. For the cumulative third quarter, net sales were 2,567,467 thousand yen, operating income was 179,232 thousand yen, ordinary income was 174,171 thousand yen, and quarterly net income was 174,484 thousand yen. The segment is a single segment focused on regenerative medicine. It explains the trend in the number of partner medical institutions and processing contracts. Recently, cost reduction and resource optimization have continued. Joint development of new processing technologies is advancing as well.\n\n### Financial position and outlook\nIn terms of financial position, total assets stood at 6,945,203 thousand yen and net assets at 6,067,369 thousand yen, with net assets increasing year over year due to retained earnings from the absorption. The full-year earnings guidance for the fiscal year ending October 2026 has been revised and announced: net sales of 3,367 million yen, operating income of 82 million yen, ordinary income of 76 million yen, net income attributable to owners of the parent of negative 124 million yen, and basic earnings per share of negative 6.26 yen. Note that the results summary indicates uncertainty in forward-looking projections.","jir_financial_highlights":"Net sales: 2,557,467 (No YoY comparison due to standalone consolidation)\nOperating income: 179,232 ( versus prior period \u2013)\nOrdinary income: 174,171 ( versus prior period \u2013)\nQuarterly net income: 174,484 ( versus prior period \u2013)\nBasic earnings per share: 8.80 ( vs prior year not available)\nTotal assets: 6,945,203 (FY end decrease by 15,622)\nNet assets: 6,067,369 (FY end increase by 79,968)","jir_category":"","jir_hashtags":"#Cellsource Co., Ltd., #Regenerative medicine-related business, #Earnings, #EarningsRevision, #HybridMedical absorption","jir_key_figures":"Net sales: 2,557,467 thousand yen\nOperating income: 179,232 thousand yen\nQuarterly net income: 174,484 thousand yen","jir_meta_title":"\u3010Cellsource Co., Ltd.\u3011FY2026 October Q3 Financial Results Summary | Net Sales 2,557,467 thousand yen, Operating Income 179,232 thousand yen","jir_meta_description":"Cellsource FY2026 Q3 financial results summary. Transition to standalone results, status of net sales and profits, revision of full-year outlook, impact of the absorption, and future initiatives explained.","jir_og_title":"Cellsource Q3 Results Highlights: Net Sales 2,557,467 thousand yen","jir_og_description":"Cellsource moves to standalone results after the absorption. Q3 net sales and profits are solid; full-year guidance revised. Emphasizing growth strategy and cost reduction going forward.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/2\\\",\\\"2026\/5\\\",\\\"2026\/8\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[0,0,0,2557.467]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/2\\\",\\\"2026\/5\\\",\\\"2026\/8\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[0,0,0,179.232]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/2\\\",\\\"2026\/5\\\",\\\"2026\/8\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[0,0,0,174.484]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"asset_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Asset Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Current assets\\\",\\\"Non-current assets\\\"],\\\"datasets\\\":[{\\\"data\\\":[5492.,1452.584],\\\"backgroundColor\\\":[\\\"#36A2EB\\\",\\\"#FF6384\\\"]}]}},\\\"options\\\":{}}\"}]","ir_related_company":59237,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-111533","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n